Allergan expands Refresh eye treatment portfolio

7 Oct 2019

A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.

Allergan has launched three new over-the-counter (OTC) Refresh Relieva products: Refresh Relieva; Refresh Relieva PF (preservative-free) multidose; and Refresh Relieva for Contacts.

Allergan expands Refresh eye treatment portfolio

This new line of artificial tear formulations available in preserved, preservative-free multidose, and a formula designed for contact lens wearers, are specially formulated to relieve discomfort due to eye dryness and to prevent further irritation. Refresh, a doctor recommended brand of artificial tears, continues to expand its portfolio by offering the only family of products in the US with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), glycerin, and HydroCell technology - Allergan's proprietary sodium chloride (NaCl) free, glycerin-based solution that enables hydration and maintains the volume of cells on the ocular surface.

"We are pleased to expand our robust artificial tear portfolio with Refresh Relieva products as we continue to exemplify our commitment to innovation in eye care. This brand-new line provides doctors and patients with three unique options to treat patients' individual needs when it comes to dry, irritated eyes and contact lens dryness," said Jag Dosanjh, Senior Vice President, Allergan US Eye Care. "With Refresh Relieva for Contacts, contact lens patients now have a new option. As the number one selling brand in preservative-free artificial tears, it was also important to us to introduce Refresh Relieva in a new, convenient preservative-free bottle. Now patients can enjoy the convenience of a multidose bottle with all the benefits of being preservative-free."

Over 26 million people in the US suffer from symptoms of eye dryness, including irritation, burning, dryness, and discomfort. Eye dryness can be caused by advanced age, contact lens wear, certain medications, other medical conditions, or environmental factors. Studies show Refresh Relieva products improve the symptoms of eye dryness in patients, with a low incidence of blur upon installation.

70% of patients reported no blur when Refresh Relieva and Refresh Relieva for Contacts was first applied.

"As eye dryness varies for each patient, I'm excited to have three new artificial tear treatment options since we know that one size doesn't fit all for patients," said Milton Hom, OD. "Different patients have different needs and Refresh Relieva provides the diversity to satisfy more patients. With a low-blur formula and HydroCell technology Refresh Relieva will be my preferred artificial tear."

Read More

Related categories

Related tags

Market News

Related news

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

21 Feb 2020

Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.

Read more 
The game is on for connected devices

The game is on for connected devices

20 Feb 2020

Global biologics markets, delivery device innovation and smart packaging ‘unpacking’ new growth opportunities for pharma.

Read more 
Management healthcare consultancy opens new offices in New York and London

Management healthcare consultancy opens new offices in New York and London

19 Feb 2020

The expansion will enable Putnam Associates to access the European market and to offer more localised support to its clients.

Read more 
CPhI South East Asia rescheduled for July 2020

CPhI South East Asia rescheduled for July 2020

18 Feb 2020

Event move ensures extra precautions and safety measures taken

Read more 
Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics

Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics

18 Feb 2020

Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant.

Read more 
Dr Reddy's to acquire Wockhardt divisions

Dr Reddy's to acquire Wockhardt divisions

18 Feb 2020

Deal sees 62 brands in multiple therapy areas and a manufacturing plant transfer to the company

Read more 
Sartorius sharpens its brand focus

Sartorius sharpens its brand focus

17 Feb 2020

The company aims to simplify its customers’ work and thus help them to achieve medical progress and make innovative medicines available faster.

Read more 
FDA success for MedPharm Centre of Excellence

FDA success for MedPharm Centre of Excellence

14 Feb 2020

The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product.

Read more 
Report predicts booming ASEAN generics export market for 2020

Report predicts booming ASEAN generics export market for 2020

13 Feb 2020

The changing opportunities are attributed to rising GMP standards and increased regional harmonization.

Read more 
Partnership formed to deliver effective biopharma industry testing

Partnership formed to deliver effective biopharma industry testing

12 Feb 2020

Stevanato and Pfeiffer Vacuum will provide biopharma companies with advanced container closure integrity analysis and testing protocols.

Read more